Coming on the heels of FDA approval in December, Axios reports that one analyst -- David Risinger of Leerink -- has called the rollout the fastest drug launch ever. This uptake is over twice that of any prior anti-obesity drug launch in the U.S., Novo Nordisk Executive Vice President U.S
Most notably [1, 12]: Hypoglycemia Hypoglycemic events are occasionally observed in GLP-1-RA use and are positively linked with concomitant use of other antidiabetic drugs
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
At its most fundamental chemical level, Vitamin C (L-ascorbic acid) functions as a highly potent electron donor, or reducing agent
Rate each on a 1-10 scale weekly
Immunohistochemistry Paraffin-embedded WAT sections were deparaffinized in xylene, rehydrated through a graded ethanol series, and subjected to heat-induced antigen retrieval